1N1 as a free ligand exists in 20 entries. Examples include: 6BSD 4QMS 3LFA

Find related ligands: Stereoisomers Similar ligands Chemical Structure Search

View summary at Ligand Expo

Chemical Component Summary

FormulaC22 H26 Cl N7 O2 S
Molecular Weight488.01
Isomeric SMILESCc1nc(Nc2ncc(s2)C(=O)Nc2c(C)cccc2Cl)cc(n1)N1CCN(CCO)CC1

Chemical Details

Formal Charge0
Atom Count59
Chiral Atom Count0
Chiral Atomsn/a
Bond Count62
Aromatic Bond Count17
Leaving Atomsn/a

Drug Info: DrugBank

DrugBank IDDB01254 Different stereochemistry
  • approved
  • investigational
DescriptionDasatinib is an oral dual BCR/ABL and Src family tyrosine kinase inhibitor approved for use in patients with chronic myelogenous leukemia (CML). The main targets of Dasatinib, are BCRABL, SRC, Ephrins and GFR.
  • anh. dasatinib
  • Anhydrous dasatinib
  • BMS dasatinib
  • Dasatinib
  • Dasatinib (anh.)
SaltsDasatinib monohydrate
Brand NamesSprycel
Affected OrganismHumans and other mammals
IndicationFor the treatment of adults with chronic, accelerated, or myeloid or lymphoid blast phase chronic myeloid leukemia with resistance or intolerance to prior therapy. Also indicated for the treatment of adults with Philadelphia chromosome-positive acute lymphoblastic leukemia with resistance or intolerance to prior therapy.
PharmacologyDasatinib is an oral dual BCR/ABL and Src family tyrosine kinase inhibitor
Mechanism of actionDasatinib, at nanomolar concentrations, inhibits the following kinases: BCR-ABL, SRC family (SRC, LCK, YES, FYN), c-KIT, EPHA2, and PDGFRβ. Based on modeling studies, dasatinib is predicted to bind to multiple conformations of the ABL kinase. In vitro, dasatinib was active in leukemic cell lines representing variants of imatinib mesylate sensitive and resistant disease. Dasatinib inhibited the growth of chronic myeloid leukemia (CML) and acute lymphoblastic leukemia (ALL) cell lines overexpressing BCR-ABL. Under the conditions of the assays, dasatinib was able to overcome imatinib resistance resulting from BCR-ABL kinase domain mutations, activation of alternate signaling pathways involving the SRC family kinases (LYN, HCK), and multi-drug resistance gene overexpression.
Route of administrationOral
  • Antineoplastic Agents
  • Antineoplastic and Immunomodulating Agents
  • Azoles
  • BCRP/ABCG2 Inhibitors
  • BCRP/ABCG2 Substrates
CAS number302962-49-8
Drug Info/Drug Targets: DrugBank 3.0: a comprehensive resource for 'omics' research on drugs. Knox C, Law V, Jewison T, Liu P, Ly S, Frolkis A, Pon A, Banco K, Mak C, Neveu V, Djoumbou Y, Eisner R, Guo AC, Wishart DS. Nucleic Acids Res. 2011 Jan; 39 (Database issue):D1035-41. | PMID:21059682